Voreloxin
Sunesis is seeking a co-development partner to accelerate timelines and to expand indications for voreloxin, which is currently in pre-registration clinical studies for the treatment of acute myeloid leukemia (AML) and ovarian cancer.
Voreloxin is a first-in-class anticancer quinolone derivative, or AQD. Voreloxin exerts potent anticancer activity through a mechanism that involves intercalation into DNA and an inhibition of topoisomerase II activity that results in replication-dependent, site-selective double-strand breaks in DNA. The DNA damage induced by voreloxin is analogous to that of the quinolone antibiotics in bacterial cells.1
We have conducted Phase 1 studies of voreloxin in patients with advanced solid tumors and with acute myeloid leukemia. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients unlikely to benefit from standard induction chemotherapy, in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. To date, clinical responses have been seen in both AML and ovarian cancer, as well as non-small cell and small cell lung cancers. Results from Sunesis' clinical and nonclinical studies of voreloxin have been reported at numerous conferences, and these posters and presentations may be found here.
As we advance voreloxin into pivotal trials, we are interested in discussing an ex-U.S. development and commercialization or worldwide co-development/co-commercialization arrangement for voreloxin.
SNS-314 Partnering Opportunity
